CN107613978A - Mek抑制剂的药物组合物及其制备方法 - Google Patents
Mek抑制剂的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN107613978A CN107613978A CN201680028975.2A CN201680028975A CN107613978A CN 107613978 A CN107613978 A CN 107613978A CN 201680028975 A CN201680028975 A CN 201680028975A CN 107613978 A CN107613978 A CN 107613978A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- kernel
- preferable
- capsule
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (26)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510283950 | 2015-05-28 | ||
CN2015102839504 | 2015-05-28 | ||
PCT/CN2016/083613 WO2016188472A1 (zh) | 2015-05-28 | 2016-05-27 | Mek抑制剂的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107613978A true CN107613978A (zh) | 2018-01-19 |
CN107613978B CN107613978B (zh) | 2019-09-20 |
Family
ID=57392340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680028975.2A Active CN107613978B (zh) | 2015-05-28 | 2016-05-27 | Mek抑制剂的药物组合物及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10350198B2 (zh) |
EP (1) | EP3305292B1 (zh) |
CN (1) | CN107613978B (zh) |
HK (1) | HK1244224B (zh) |
WO (1) | WO2016188472A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024083184A1 (zh) * | 2022-10-20 | 2024-04-25 | 西藏海思科制药有限公司 | 一种egfr抑制剂的药物组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102020651A (zh) * | 2010-11-02 | 2011-04-20 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102020657A (zh) * | 2009-09-11 | 2011-04-20 | 上海艾力斯医药科技有限公司 | 稠合杂芳基衍生物、制备方法及其应用 |
CN105315291B (zh) * | 2014-08-05 | 2019-02-01 | 正大天晴药业集团股份有限公司 | 一种6-芳基氨基吡啶酮甲酰胺化合物的结晶及其制备方法 |
-
2016
- 2016-05-27 CN CN201680028975.2A patent/CN107613978B/zh active Active
- 2016-05-27 WO PCT/CN2016/083613 patent/WO2016188472A1/zh active Application Filing
- 2016-05-27 EP EP16799359.1A patent/EP3305292B1/en active Active
- 2016-05-27 US US15/577,227 patent/US10350198B2/en active Active
-
2018
- 2018-03-19 HK HK18103796.0A patent/HK1244224B/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102020651A (zh) * | 2010-11-02 | 2011-04-20 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024083184A1 (zh) * | 2022-10-20 | 2024-04-25 | 西藏海思科制药有限公司 | 一种egfr抑制剂的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN107613978B (zh) | 2019-09-20 |
EP3305292A1 (en) | 2018-04-11 |
US10350198B2 (en) | 2019-07-16 |
WO2016188472A1 (zh) | 2016-12-01 |
US20180147192A1 (en) | 2018-05-31 |
HK1244224B (zh) | 2020-06-12 |
EP3305292A4 (en) | 2019-03-20 |
EP3305292B1 (en) | 2022-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6560289B2 (ja) | 新たな医薬組成物 | |
WO2022022369A1 (zh) | 一种托法替布或其盐的缓释制剂及其制备方法 | |
CN101048140A (zh) | 用于治疗癌症的新药物组合物 | |
CN102805733A (zh) | 颗粒制剂及其制造方法 | |
CN104523686B (zh) | 盐酸阿考替胺药物制剂及其制备方法 | |
CN102552256A (zh) | 一种艾普拉唑肠溶胶囊及其制备方法 | |
CN105343028A (zh) | 一种诺氟沙星的药物组合物及其制备方法 | |
CN105412023A (zh) | 一种琥珀酸呋罗曲坦控释颗粒及其制备方法 | |
CN107613978B (zh) | Mek抑制剂的药物组合物及其制备方法 | |
CN111214456A (zh) | 伏立康唑干混悬剂及其制备方法 | |
CN107115325A (zh) | 一种琥珀酸呋罗曲坦胶囊及其制备方法 | |
US20060063832A1 (en) | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof | |
WO2005077357A1 (en) | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof | |
CN102526233B (zh) | 一种含有乌头碱的多单元肠溶制剂及其制备方法 | |
CN106619646A (zh) | 一种替吉奥组合物的制备方法 | |
CN104147012B (zh) | 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂 | |
US20220233550A1 (en) | Parp inhibitor pellet preparation and preparation process therefor | |
WO2020116447A1 (ja) | 難溶性薬物の固体分散体 | |
JP2024501691A (ja) | トリアゾロピラジン誘導体化合物を有効成分とする薬学的組成物のタブレット錠の製造方法 | |
CN114555059A (zh) | 含硝羟喹啉的药物组合物、硝羟喹啉片剂及其制备方法和用途 | |
CN105919977A (zh) | 一种托匹司他控释胶囊及其制备方法 | |
CN106420759A (zh) | 一种替吉奥组合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1244224 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: He Xiongxiong Inventor after: Dong Ping Inventor after: Cai Jiahui Inventor after: Lu Xifeng Inventor after: Xu Jiao Inventor after: Jiang Bo Inventor after: Deng Zhenxue Inventor after: Shan Shan Inventor before: He Xiongxiong Inventor before: Dong Ping Inventor before: Cai Jiahui Inventor before: Lu Xifeng Inventor before: Xu Jiao Inventor before: Jiang Bo Inventor before: Deng Zhenxue Inventor before: Shan Shan |